France news - the latest biotech news from Labiotech.eu

Home France Page 35

Latest Posts

rafaele tordjman sofinnova

News and Trends 8 Nov 2016

Has Gender Diversity in Biotech changed? “No”, says Managing partner of Sofinnova #BIOEurope

In our second interview of BIO-Europe, we talked about gender diversity with Rafaèle Tordjman, one of the managing partners of Sofinnova Partners, a top Biotech VC in Europe. She has been very active in making biotech more open to women, and I wanted to know more about her analysis of the situation. I had met […]

November 8, 2016 - 1 minutemin - By Philip Hemme

costantini ose immunotherapeutics

News and Trends 7 Nov 2016

Catching Up with the French Leader in Immuno-Oncology #BIOEurope

Despite the deflating attitudes towards immuno-oncology, OSE Immunotherapeutics is forging ahead. We caught up with the CEO, Dominique Costantini, at BIO Europe to make our first video Interview. OSE Immunotherapeutics is developing immunotherapy products against invasive and metastatic late-stage cancers. Memopi is one of its key technologies, and it is currently under development for ovarian, colon and breast […]

November 7, 2016 - 1 minutemin - By Philip Hemme

shutterstock 203186917

News and Trends 7 Nov 2016

Green Light for Genfit to Tackle another Liver Disease

The FDA has cleared Genfit’s IND application to treat a second liver disease with a big unmet clinical need. With this new step forward, the company gets even closer to become the leader in liver disease treatments. After a very successful fundraising last week, Genfit is kicking off the week with good news from the […]

November 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

shutterstock 270990392

News and Trends 5 Nov 2016

Would you Taste this Gene-Edited Dinner?

Genetic engineering can make food healthier, improve nutrition and reduce environmental impact. To demonstrate its potential, Cellectis hosted a dinner featuring futuristic food technology. Cellectis is a French company that develops immuno-oncology therapies and became famous last year when its CAR-T treatment saved a 1-year old girl from leukemia. Its gene-editing TALEN technology is also used by […]

November 5, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Sanofi regeneron rheumatoid arthritis salurimab

News and Trends 31 Oct 2016

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […]

October 31, 2016 - 3 minutesmins - By Dani Bancroft

shutterstock 485784082

News and Trends 25 Oct 2016

The First Peanut Allergy Therapy might soon hit the Shelves

DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate […]

October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

signing contract PORTRAIT IMAGES ASIA BY NONWARIT fi

News and Trends 17 Oct 2016

TxCell lines up another duck in its CAR-Treg campaign

Novartis veteran Li Zhou has joined TxCell as the VP of cell engineering to oversee CAR-Treg programs for autoimmune and inflammation diseases. The French Treg maverick, TxCell, has hoovered up more talent to pioneer its hybrid CAR-Treg therapies: Li Zhou will be the new Vice President of the company’s cell engineering division. What we are doing here with CAR-Tregs to treat […]

October 17, 2016 - 2 minutesmins - By Evelyn Warner

chimp apple2499 fi

News and Trends 17 Oct 2016

It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia

The Committee on Medicinal Products for Human Use (CHMP) has handed down a pair of positive opinions of Opdivo and AbbVie’s leukemia therapy in their quests for EMA approval. Before the European Commission reviews an application for market authorization, it crosses the collective desk of the Committee on Medicinal Products for Human Use (CHMP). If […]

October 17, 2016 - 2 minutesmins - By Evelyn Warner

Screenshot 2016 10 12 at 12.23.30 PM e1476267908354

News and Trends 12 Oct 2016

Transgene teams up with big Players against HPV Head and Neck Cancer

Transgene is partnering with Merck and Pfizer to develop a combined therapy for head and neck cancer squamous cell carcinoma (HNSCC) caused by human papiloma virus (HPV) infections. A successful outcome will let the team access a €2B market niche. Transgene has been struggling for a while: last year it had to fire 40% of its workforce […]

October 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Picture1 e1475237972877

News and Trends 10 Oct 2016

Meet the French CEO who wants to Break Barriers to Drug Delivery

The objective of the French biotechnology company, Vect-Horus, is to leverage its technology, VECTrans, to facilitate the delivery of drugs into the brain and other organs. For this innovation, the company recently received the Frost & Sullivan 2016 Leadership award, which independently recognizes companies for demonstrating excellence in developing innovative technologies and practices within an industry. […]

October 10, 2016 - 5 minutesmins - By Marie Godar

scissors couture optimarc fi

News and Trends 7 Oct 2016

Meet the ‘Haut-Couturiers’ of Bioengineering

It’s time to ride the slopes and land in the French alpine capital, Grenoble, to meet our Biotech of the week, BGene Genetics. This start-up is changing the bug factory sector! BGene has developed a method to edit the chromosomes of a bug to produce proteins rather than inserting a plasmid, and this proprietary technology […]

October 7, 2016 - 3 minutesmins - By Jerome Topsent

liver bluebay fi

News and Trends 6 Oct 2016

NASH Maverick continues Rampage with €34M Cash Injection

Genfit just added €34M to its cash pile through private placement to bankroll the development of its succeeding lead candidate, Elafibranor. Genfit has had a good year. Earlier this year, the company enrolled its first patient in Phase III clinical trails for Non-Alcoholic Stato-Hepatitis (NASH), and last month, it launched a new non-invasive diagnostic program. It’s […]

October 6, 2016 - 2 minutesmins - By Evelyn Warner

ADVERTISEMENT